EP
DNTH icon

Eversept Partners’s Dianthus Therapeutics DNTH Stock Holding History

Eversept Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,430
Closed -$1.45M – 113
2021
Q3 		$1.45M Buy
+12,430
New +$1.45M 0.1% 86

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners's DNTH Position: Q4 2021 in Review

Eversept Partners sold out of Dianthus Therapeutics (DNTH) in Q4 2021, closing a stake of 12,430 shares — an estimated $1.45M sold.

Eversept Partners first reported a position in DNTH in Q3 2021 and held it in 1 quarter. The position peaked at $1.45M in Q3 2021. 94 funds tracked by Wall St. Rank hold DNTH as of Q4 2021.

  • Eversept Partners reported no remaining Dianthus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Eversept Partners sold 12,430 Dianthus Therapeutics shares in Q4 2021, an estimated $1.45M.
  • Eversept Partners first reported a position in Dianthus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Eversept Partners's Dianthus Therapeutics position peaked at $1.45M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2021.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.